Myriad Genetics Inc (MYGN) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Myriad Genetics Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
High 4.04 at 9:30 am ET, low 3.89 at 3:45 pm ET.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
the bull case· 3
4
of the funds on file reporting a position in MYGN
n-portas of Jun 30 '26+20.79%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '2610
disclosed supplier and customer ties in SEC filings
sec filingsedgarthe bear case· 3
8 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '260.16%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '265 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Mar 29 '27 report. Not a forecast, not advice.
Of the 6 companies Myriad Genetics Inc moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2835, In Vitro & In Vivo Diagnostic Substances, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
194 managers report a position worth $508.3M between them, and 25 of them hold 80% of it.
MYGN (Myriad Genetics Inc) has 7 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.